International Nonproprietary Names for Pharmaceutical Substances (INN)

Recommended International Nonproprietary Names (Rec. INN): List 35

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–65) and Recommended (1–31) International Nonproprietary Names can be found in *Cumulative List No. 8, 1992.*

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales recommandées (DCI Rec): Liste 35

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–65) et recommandées (1–31) dans la *Liste récapitulative No. 8, 1992.*

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 35

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–65) y Recomendadas (1–31) se encuentran reunidas en *Cumulative List No. 8, 1992.*

Recommended INN (Latin, English, French, Spanish) DCI Recommandée DCI Recomendada	*Chemical name or description and Molecular formula Nom chimique ou description et Formule brute Nombre químico o descripción y Fórmula empírica*
acidum gadoxeticum	
gadoxetic acid	dihydrogen [*N*-[(2*S*)-2-[bis(carboxymethyl)amino]-3-(*p*-ethoxyphenyl)propyl]-*N*-[2-[bis(carboxymethyl)amino]ethyl]glycinato(5-)]gadolinate(2-)
acide gadoxétique	dihydrogéno[*N*-[(2*S*)-2-[bis(carboxyméthyl)amino]-3-(4-éthoxyphényl)propyl]-*N*-[2-[bis(carboxyméthyl)amino]éthyl]glycinato(5-)]gadolinate(2-)
ácido gadoxetico	dihidrógeno [*N*-[(2*S*)-2-[bis(carboximetil)amino]-3-(*p*-etoxifenil)propil]-*N*-[2-[bis(carboximetil)amino]etil]glicinato(5-)]gadolinato(2-)
	$C_{23}H_{30}GdN_3O_{11}$
acidum ibandronicum	
ibandronic acid	[1-hydroxy-3-(methylpentylamino)propylidene]diphosphonic acid
acide ibandronique	acide [1-hydroxy-3-[méthyl(pentyl)amino]propylidène]bisphosphonique
ácido ibandrónico	ácido [1-hidroxi-3-(metilpentilamino)propilideno]difosfónico
	$C_9H_{23}NO_7P_2$
acidum olpadronicum	
olpadronic acid	[3-(dimethylamino)-1-hydroxypropylidene]diphosphonic acid
acide olpadronique	acide [3-(diméthylamino)-1-hydroxypropylidène]bisphosphonique
ácido olpadrónico	ácido [3-(dimetilamino)-1-hidroxipropilideno]difosfónico
	$C_5H_{15}NO_7P_2$
acidum zoledronicum	
zoledronic acid	(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
acide zolédronique	acide [1-hydroxy-2-(1*H*-imidazol-1-yl)éthylidène]bisphosphonique
ácido zoledrónico	ácido (1-hidroxi-2-imidazol-1-iletiliden)difosfónico
	$C_5H_{10}N_2O_7P_2$
acitazanolastum	
acitazanolast	3'-(1*H*-tetrazol-5-yl)oxanilic acid
acitazanolast	acide *N*-[3-(1*H*-tétrazol-5-yl)phényl]oxamique
acitazanolast	ácido 3'-(1*H*-tetrazol-5-il)oxanílico
	$C_9H_7N_5O_3$

adefovirum

adefovir	[[2-(6-amino-9*H*-purin-9-yl)ethoxy]methyl]phosphonic acid
adéfovir	acide [[2-(6-amino-9*H*-purin-9-yl)éthoxy]méthyl]phosphonique
adefovir	àcido [[2-(6-amino-9*H*-purin-9-il)etoxi]metil]fosfónico
	$C_8H_{12}N_5O_4P$

afelimomabum

afelimomab	immunoglobulin G 3 (mouse monoclonal LU54107 Fab' fragment γ-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal LU54107 κ-chain, dimer
afélimomab	immunoglobuline G 3 (chaîne γ du fragment Fab' de l'anticorps monoclonal de souris LU54107 anti-facteur de nécrose tumorale α humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris LU54107
afelimomab	inmunoglobulina G 3 (cadena γ del fragmento Fab' del anticuerpo monoclonal de ratón LU54107 anti-factor de necrosis tumoral α humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón LU54107

alniditanum

alniditan	2-[[3-[[(*R*)-2-chromanylmethyl]amino]propyl]amino]-1,4,5,6-tetrahydropyrimidine
alniditan	*N*-[[(2*R*)-3,4-dihydro-2*H*-chromén-2-yl]méthyl]-*N'*-(1,4,5,6-tétrahydropyrimidin-2-yl)propan-1,3-diyldiamine
alniditan	2-[[3-[[(*R*)-2-cromanilmetil]amino]propil]amino]-1,4,5,6-tetrahidropirimidina
	$C_{17}H_{26}N_4O$

anakinrum

anakinra	N^2-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)
anakinra	N^2-L-méthionylantagoniste du récepteur de l'interleukine-1 (isoforme x humaine réduite)
anakinra	N^2-L-metionil antagonista del receptor de interleukina 1 (isoforma x reducida, humana)
	$C_{759}H_{1186}N_{208}O_{232}S_{10}$

anastrozolum

anastrozole	α,α,α',α'-tetramethyl-5-(1*H*-1,2,4-triazol-1-ylmethyl)-*m*-benzenediacetonitrile
anastrozole	2,2'-diméthyl-2,2'-[5-[(1*H*-1,2,4-triazol-1-yl)méthyl]benzène-1,3-diyl]= dipropanenitrile
anastrozol	α,α,α',α'-tetrametil-5-(1*H*-1,2,4-triazol-1-ilmetil)-*m*-bencendiacetonitrilo
	$C_{17}H_{19}N_5$

apaxifyllinum

apaxifylline	(-)-(*S*)-8-(3-oxocyclopentyl)-1,3-dipropylxanthine
apaxifylline	(-)-(*S*)-8-(-3-oxocyclopentyl)-1,3-dipropyl-3,7-dihydro-1*H*-purine-2,6-dione
apaxifilina	(-)-(*S*)-8-(3-oxociclopentil)-1,3-dipropilxantina
	$C_{16}H_{22}N_4O_3$

aptiganelum

aptiganel	1-(*m*-ethylphenyl)-1-methyl-3-(1-naphthyl)guanidine
aptiganel	1-(3-éthylphényl)-1-méthyl-3-(naphtalén-1-yl)guanidine
aptiganel	1-(*m*-etilfenil)-1-metil-3-(1-naftil)guanidina
	$C_{20}H_{21}N_3$

atexakinum alfa

atexakin alfa	1-(1-L-alanyl-L-proline)interleukin 6 (human clone HGF15 protein moiety reduced), cyclic (44→50), (73→83)-bis(disulfide)
atexakine alfa	(44→50), (73→83)-bis(disulfure cyclique) de la [1-(1-L-alanyl-L-proline)]= interleukine 6 (partie protéique réduite de la substance issue du clone humain HGF15)
atexakina alfa	1-(1-L-alanil-L-prolina)interleukina 6 (fracción proteica reducida del clon humano HGF15), bis(disulfuro)cíclico (44→50), (73→83)
	$C_{917}H_{1483}N_{255}O_{288}S_9$

atibepronum

atibeprone	7-[(5-isopropyl-1,3,4-thiadiazol-2-yl)methoxy]-3,4-dimethylcoumarin
atibéprone	3,4-diméthyl-7-[[5-(1-méthyléthyl)-1,3,4-thiadiazol-2-yl]méthoxy]-2*H*-chromén-2-one
atibeprona	7-[(5-isopropil-1,3,4-tiadiazol-2-il)metoxi]-3,4-dimetilcumarina
	$C_{17}H_{18}N_2O_3S$

atorvastatinum

atorvastatin	(β*R*,δ*R*)-2-(*p*-fluorophenyl)-β,δ-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
atorvastatine	acide (3*R*,5*R*)-7-[2-(4-fluorophényl)-5-(1-méthyléthyl)-3-phényl-4-[(phényl= amino)carbonyl]-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoïque
atorvastatina	ácido (β*R*,δ*R*)-2-(*p*-fluorofenil)-β,δ-dihidroxi-5-isopropil-3-fenil-4-(fenilcarbamoil)pirrol-1-heptanoico
	$C_{33}H_{35}FN_2O_5$

azimilidum

azimilide	1-[[5-(*p*-chlorophenyl)furfurylidene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]= hydantoin
azimilide	1-[[[5-(4-chlorophényl)furan-2-yl]méthylène]amino]-3-[4-(4-méthylpipérazin-1-yl)butyl]imidazolidine-2,4-dione
azimilida	1-[[5-(*p*-clorofenil)furfurilidenlamino]-3-[4-(4-metil-1-piperazinil)butil]hidantoina
	$C_{23}H_{28}ClN_5O_3$

balaziponum

balazipone	*m*-(2-acetyl-3-oxo-1-butenyl)benzonitrile
balazipone	3-(2-acétyl-3-oxobut-1-énylbenzonitrile
balazipona	*m*-(2-acetil-3-oxo-1-butenil)benzonitrilo
	$C_{13}H_{11}NO_2$

balofloxacinum

balofloxacin (±)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)piperidino]-4-oxo-3-quinolinecarboxylic acid

balofloxacine acide (*RS*)-1-cyclopropyl-6-fluoro-8-méthoxy-7-[3-(méthylamino)pipéridin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

balofloxacino ácido (±)-1-ciclopropil-6-fluoro-1,4-dihidro-8-metoxi-7-[3-(metilamino)=piperidino]-4-oxo-3-quinolincarboxílico

$C_{20}H_{24}FN_3O_4$

basifunginum

basifungin *N*-[(2*R*,3*R*)-2-hydroxy-3-methylvaleryl]-*N*-methyl-L-valyl-L-phenylalanyl-*N*-methyl-L-phenylalanyl-L-prolyl-L-alloisoleucyl-*N*-methyl-L-valyl-L-leucyl-3-hydroxy-*N*-methyl-L-valine α_1-lactone

basifungine α_1-lactone de la [*N*-[(2*R*,3*R*)-2-hydroxy-3-méthylpentanoyl]-*N*-méthyl-L-valyl]-L-phénylalanyl-(*N*-méthyl-L-phénylalanyl)-L-prolyl-L-allo-isoleucyl-(*N*-méthyl-L-valyl)-L-leucyl-(3-hydroxy-*N*-méthyl-L-valine)

basifungina *N*-[(2*R*,3*R*)-2-hidroxi-3-metilvaleril]-*N*-metil-L-valil-L-fenilalanil-*N*-metil-L-fenilalanil-L-prolil-L-aloisoleucil-*N*-metil-L-valil-L-leucil-3-hidroxi-*N*-metil-L-valina α_1-lactona

$C_{60}H_{92}N_8O_{11}$

berupipamum

berupipam (+)-(5*S*)-5-(5-bromo-2,3-dihydro-7-benzofuranyl)-8-chloro- 2,3,4,5-tetrahydro-3-methyl-1*H*-3-benzazepin-7-ol

bérupipam (+)-(*S*)-5-(5-bromo-2,3-dihydrobenzofuran-7-yl)-8-chloro-3-méthyl-2,3,4,5-tétrahydro-1*H*-3-benzazépin-7-ol

berupipam (+)-(5*S*)-5-(5-bromo-2,3-dihidro-7-benzofuranil)-8-cloro- 2,3,4,5-tetrahidro-3-metil-1*H*-3-benzazepin-7-ol

$C_{19}H_{19}BrClNO_2$

bervastatinum

bervastatin ethyl (±)-(3*R**,5*S**,6*E*)-7-[4-(*p*-fluorophenyl)spiro[2*H*-1-benzopyran-2,1'-cyclopentan]-3-yl]-3,5-dihydroxy-6-heptenoate

bervastatine (±)-(6*E*)-(3*RS*,5*SR*)-7-[4-(4-fluorophényl)spiro[2*H*-chromène-2,1'-cyclopentane]-3-yl]-3,5-dihydroxyhept-6-énoate d'éthyle

bervastatina (±)-(3*R**,5*S**,6*E*)-7-[4-(*p*-fluorofenil)espiro[2*H*-1-benzopiran-2,1'-ciclopentan]-3-i]-3,5-dihidroxi-6-heptenoato de etilo

$C_{28}H_{31}FO_5$

betasizofiranum

betasizofiran scleroglucan or poly[→3(*O*-β-D-glucopyranosyl-(1→3)-*O*-[β-D-glucopyranosyl-(1→6)]-*O*-β-D-glucopyranosyl-(1→3)-*O*-β-D-glucopyranosyl-(1→] produced by *Sclerotium rolfsii*; relative molecular mass is about 5.10^6

bétasizofiran scléroglucan ou poly[→3(*O*-β-D-glucopyranosyl-(1→3)-*O*-[β-D-glucopyranosyl-(1→6)]-*O*-β-D-glucopyranosyl-(1→3)-*O*-β-D-glucopyranosyl-(1→] produit par *Sclerotium rolfsii*; la masse moléculaire relative est voisine de 5.10^6

betasizofiran escleroglucano ó poli[→3(*O*-β-D-glucopiranosil-(1→3)-*O*-[β-D-glucopiranosil-(1→6)]-*O*-β-D-glucopiranosil-(1→3)-*O*-β-D-glucopiranosil-(1→] producido por *Sclerotium rolfsii*; la masa molecular relativa es aproximadamente de 5.10^6

$(C_{24}H_{40}O_{20})_n$

bivalirudinum

bivalirudin — D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine

bivalirudine — D-phénylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparaginyl-glycyl-L-α-aspartyl-L-phénylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine

bivalirudina — D-fenilalanil-L-prolil-L-arginil-L-prolilglicilglicilglicilglicil-L-asparraginilglicil-L-α-aspartil-L-fenilalanil-L-α-glutamil-L-α-glutamil-L-isoleucil-L-prolil-L-α-glutamil-L-α-glutamil-L-tirosil-L-leucina

$C_{98}H_{139}N_{24}O_{33}$

candesartanum

candesartan — 2-ethoxy-1-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]-7-benzimidazolecarboxylic acid

candésartan — acide 2-éthoxy-1-[4-[2-(1*H*-tétrazol-5-yl)phényl]benzyl]-1*H*-benzimidazole-7-carboxylique

candesartan — ácido 2-etoxi-1-[*p*-(*o*-1*H*-tetrazol-5-ilfenil)bencil]-7-bencimidazolcarboxílico

$C_{24}H_{20}N_6O_3$

capecitabinum

capecitabine — pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

capécitabine — [1-(5-désoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate de pentyle

capecitabina — 1-(5-desoxi-β-D-ribofuranosil)-5-fluoro-1,2-dihidro-2-oxo-4-pirimidincarbamato de pentilo

$C_{15}H_{22}FN_3O_6$

cartasteinum

cartasteine — (*S*)-3-[*N*-[(*R*)-2-mercaptopropionyl]glycyl]-4-thiazolidinecarboxylic acid

cartastéine — acide (4*S*)-3-[2-[[(2*R*)-2-mercaptopropanoyl]amino]acétyl]thiazolidine-4-carboxylique

cartasteína — ácido (*S*)-3-[*N*-[(*R*)-2-mercaptopropionil]glicil]-4-tiazolidinecarboxílico

$C_9H_{14}N_2O_4S_2$

cefluprenamum

cefluprenam — (-)-[(*E*)-3-[(6*R*,7*R*)-7-[2-(5-amino-1,2,4-thiadiazol-3-yl)glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-en-3-yl]allyl](carbamoyl=methyl)ethylmethylammonium hydroxide, inner salt, 7^2-(*Z*)-[*O*- (fluoromethyl)=oxime]

céfluprénam — (-)-(2-amino-2-oxoéthyl)[(*E*)-3-[(6*R*,7*R*)-7-[[(*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(fluorométhoxy)imino]acétyl]amino]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4 2.0]oct-2-én-3-yl]prop-2-ényl]éthylméthylammonium

cefluprenam — hidróxido de (-)-[(*E*)-3-[(6*R*,7*R*)-7-[2-(5-amino-1,2,4-tiadiazol-3-il)glioxilamido]-2-carboxi-8-oxo-5-tia-1-azabiciclo [4.2.0]oct-2-en-3-il]alil](carbamoilmetil)=etilmetilamonio, sal interna, 7^2-(*Z*)-[*O*-(fluorometil)oxima

$C_{20}H_{25}FN_8O_6S_2$

cefoselisum

cefoselis (-)-5-amino-2-[[(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-(2-hydroxyethyl)= pyrazolium hydroxide, inner salt, 7^2-(*Z*)-(*O*-methyloxime)

céfosélis (-)-5-amino-2-[[(6*R*,7*R*)-7-[[(*Z*)-2-(2-aminothiazol-4-yl)-2-(méthoxyimino)= acétyl]amino]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-én-3-yl]= méthyl]-1-(2-hydroxyéthyl)-1*H*-pyrazolium

cefoselis (-)-5-amino-2-[[(6*R*,7*R*)-7-[[(*Z*)-2-(2-aminotiazol-4-il)-2-(metoxiimino)acetil]= amino]-2-carboxilato-8-oxo-5-tia-1- azabiciclo[4.2.0]oct-2-en-3-il]metil]-1-(2 hidroxietil)-1*H*-pirazolio

$C_{19}H_{22}N_8O_6S_2$

cidofovirum

cidofovir [[(*S*)-2-(4-amino-2-oxo-1(2*H*)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]= phosphonic acid

cidofovir acide [[(1*S*)-2-(4-amino-2-oxopyrimidin-1(2*H*)-yl)-1-(hydroxyméthyl)éthoxy]= méthyl]phosphonique

cidofovir àcido [[(*S*)-2-(4-amino-2-oxo-1(2*H*)-pirimidinil)-1-(hidroximetil)etoxi]metil]= fosfónico

$C_8H_{14}N_3O_6P$

cilmostimum

cilmostim 1-223-colony-stimulating factor 1 (human clone p3ACSF-69 protein moiety reduced) dimer, cyclic (7→90), (7'→ 90'), (31→31'), (48→139), (48'→ 139'), (102→146), (102'→ 146')-heptakis(disulfide)

cilmostime (7→90), (7'→ 90'), (31→31'), (48→139), (48'→ 139'), (102→146), (102'→ 146')-heptakis(disulfure cyclique) du dimère de 1-223-facteur 1 de stimulation des colonies (partie protéique réduite du clone humain p3ACSF-69)

cilmostim (7→90), (7'→ 90'), (31→31'), (48→139), (48'→ 139'), (102→146), (102'→ 146')-heptakis(disulfuro cíclico) del dímero de 1- 223-factor 1 de estimulación de colonias (fracción proteica reducida del clon humano p3ACSF-69)

$C_{2198}H_{3430}N_{588}O_{704}S_{28}$

cipamfylline

cipamfylline 8-amino-1,3-bis(cyclopropylmethyl)xanthine

cipamfylline 8-amino-1,3-bis(cyclopropylméthyl)-3,7-dihydro-1*H*-purine-2,6-dione

cipamfilina 8-amino-1,3-bis(ciclopropilmetil)xantina

$C_{13}H_{17}N_5O_2$

cromoglicas lisetilum

cromoglicate lisetil diethyl 5,5'-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4*H*-1-benzopyran-2-carboxylate], ester with L-lysine

cromoglicate lisétil (+)-5,5'-[[2-[[(2*S*)-2,6-diaminohexanoyl]oxy]propane-1,3-diyl]dioxy]bis(4-oxo-4*H*-chromène-2-carboxylate d'éthyle)

cromoglicato lisetil 5,5'-[(2-hidroxitrimetileno)dioxi]bis[4-oxo-4*H*-1-benzopirano-2-carboxilato] de dietilo, éster con L-lisina

$C_{33}H_{36}N_2O_{12}$

daclixímabum

daclixímab — immunoglobulin G 1 (human-mouse monoclonal clone 1H4 γ-chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer

daclixímab — immunoglobuline G 1 (chaîne γ de l'anticorps monoclonal du clone homme-souris 1H4 dirigé contre le récepteur de l'interleukine 2 humain), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal du clone homme-souris 1H4

daclixímab — inmunoglobulina G 1(cadena γ del anticuerpo monoclonal del clon humano-murino 1H4 anti-receptor de la interleukina 2 humano), dimero del disulfuro con la cadena ligera del anticuerpo monoclonal del clon humano-murino

$C_{6394}H_{9888}N_{1696}O_{2012}S_{44}$

delavirdinum

delavirdine — 1-[3-(isopropylamino)-2-pyridyl]-4-[(5-methanesulfonamidoindol-2-yl)= carbonyl]piperazine

délavirdine — 1-[3-[(1-méthyléthyl)amino]pyridin-2-yl]-4-[[5-[(méthylsulfonyl)amino]-1*H*-indol-2-yl]carbonyl]pipérazine

delavirdina — 1-[3-(isopropilamino)-2-piridil]-4-[(5-metanosulfonamidoindol-2-il)carbonil]= piperazina

$C_{22}H_{28}N_6O_3S$

dexpemedolacum

dexpemedolac — (1*S*,4*R*)-4-benzyl-1-ethyl-1,3,4,9-tetrahydropyrano[3,4-*b*]indole-1-acetic acid

dexpémédolac — acide 2-[(1*S*,4*R*)-4-benzyl-1-éthyl-1,3,4,9-tétrahydropyrano[3,4-*b*]indol-1-yl]= acétique

dexpemedolaco — ácido (1*S*,4*R*)-4-bencil-1-etil-1,3,4,9-tetrahidropirano[3,4-*b*]indol-1-acético

$C_{22}H_{23}NO_3$

docetaxelum

docetaxel — (2*R*,3*S*)-*N*-carboxy-3-phenylisoserine, *N*-*tert*-butyl ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate

docétaxel — (2*R*,3*S*)-3-[[(1,1-diméthyléthoxy)carbonyl]amino]-2-hydroxy-3-phénylpropanoate de 4-(acétyloxy)-2α-(benzoyloxy)-5β,20-époxy-1,7β,10β-trihydroxy-9-oxotax-11-én-13α-yle

docetaxel — (2*R*,3*S*)-*N*-carboxi-3-fenilisoserina, *N*-*terc*-butil éster, 13-éster con 5β-20-epoxi-1,2α,4,7β,10β,13α-hexahidroxitax-11-en-9-ona 4-acetato 2-benzoato

$C_{43}H_{53}NO_{14}$

ebalzotanum

ebalzotan — (*R*)-*N*-isopropyl-3-(isopropylpropylamino)-5-chromancarboxamide

ébalzotan — (3*R*)-*N*-(1-méthyléthyl)-3-[(1-méthyléthyl)propylamino]-3,4-dihydro-2*H*-chromène-5-carboxamide

ebalzotan — (*R*)-*N*-isopropil-3-(isopropilpropilamino)-5-cromancarboxamida

$C_{19}H_{30}N_2O_2$

efegatranum

efegatran — *N*-methyl-D-phenylalanyl-*N*-[(1*S*)-1-formyl-4-guanidinobutyl]-L-prolinamide

éfégatran — (2*S*)-*N*-[(1*S*)-1-formyl-4-guanidinobutyl]-1-[(2*R*)-2-(méthylamino)-3-phénylpropanoyl]pyrrolidine-2-carboxamide

efegatran — *N*-metil-D-fenilalanil-*N*-[(1*S*)-1-formil-4-guanidinobutil]-L-prolinamida

$C_{21}H_{32}N_6O_3$

efletirizinum

efletirizine — [2-[4-[bis(*p*-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid

éflétirizine — acide 2-[2-[4-[bis(4-fluorophényl)méthyl]pipérazin-1-yl]éthoxy]acétique

efletirizina — ácido [2-[4-[bis(*p*-fluorofenil)metil]-1-piperazinil]etoxi]acético

$C_{21}H_{24}F_2N_2O_3$

elisartanum

elisartan — (±)-1-hydroxyethyl 2-butyl-4-chloro-1-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]-imidazole-5-carboxylate, ethyl carbonate (ester)

élisartan — 2-butyl-4-chloro-1-[4-[2-(1*H*-tétrazol-5-yl)phényl]benzyl]-1*H*-imidazol-5-carboxylate de (*RS*)-1-[(éthoxycarbonyl)oxy]éthyle

elisartan — (±)-2-butil-4-cloro-1-[*p*-(*o*-1*H*-tetrazol-5-ilfenil)bencil]imidazol-5-carboxilato,etil carbonato de 1-hidroxietilo (éster)

$C_{27}H_{29}ClN_6O_5$

epoetinum epsilonum

epoetin epsilon — 1-165-erythropoietin (human clone λHEPOFL13 protein moiety), glycoform ε

époétine epsilon — 1-165-érythropoïétine (partie protéique du clone humain λHEPOFL13), forme glycosylée ε

epoetina epsilon — 1-165-eritropoietina (fracción proteica del clon humano λHEPOFL13), forma glicosilada ε

$C_{809}H_{1301}N_{229}O_{240}S_5$
(for non-glycosylated protein)
(pour la protéine non glycosylée)
(fracción proteica no glicosilada)

eprosartanum

eprosartan — (*E*)-2-butyl-1-(*p*-carboxybenzyl)-α-2-thienylimidazole-5-acrylic acid

éprosartan — acide (*E*)-3-[2-butyl-1-(4-carboxybenzyl)-1*H*-imidazol-5-yl]-2-[(2-thiényl)-méthyl]prop-2-énoïque

eprosartan — ácido (*E*)-2-butil-1-(*p*-carboxibencil)-α-2-tienilimidazol-5-acrílico

$C_{23}H_{24}N_2O_4S$

eptacogum alfa (activatum)

eptacog alfa (activated) — blood-coagulation factor VII (human clone λHVII2463 protein moiety)

eptacog alfa (activé) — facteur VII de coagulation sanguine (partie protéique de la substance issue du clone humain λHVII2463)

eptacog alfa (activado) — factor de coagulación VII (fracción proteica del clon humano λHVII2463)

$C_{2621}H_{4056}N_{728}O_{812}S_{36}$

ersentilidum

ersentilide — 4'-[(2*S*)-2-hydroxy-3-[[2-(*p*-imidazol-1-ylphenoxy)ethyl]amino]propoxy]= methanesulfonanilide

ersentilide — *N*-[4-[[(*S*)-2-hydroxy-3-[[2-[4-(1*H*-imidazol-1-yl)phénoxy]éthyl]amino]propyl]= oxy]phényl]méthanesulfonamide

ersentilida — 4'-[(2*S*)-2-hidroxi-3-[[2-(*p*-imidazol-1-ilfenoxi)etil]amino]propoxi]= metansulfonanilida

$C_{21}H_{26}N_4O_5S$

examorelinum

examorelin — L-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide

examoréline — L-histidyl-(2-méthyl-D-tryptophyl)-L-alanyl-L-tryptophyl-D-phénylalanyl-L-lysinamide

examorelina — L-histidil-2-metil-D-triptofil-L-alanil-L-triptofil-D-fenilalanil-L-lisinamida

$C_{47}H_{58}N_{12}O_6$

fampridinum

fampridine — 4-aminopyridine

fampridine — pyridin-4-ylamine

fampridina — 4-aminopiridina

$C_5H_6N_2$

faropenemum

faropenem — (+)-(5*R*,6*S*)-6-[(1*R*)-1-hydroxyethyl]-7-oxo-3-[(2*R*)-tetrahydro-2-furyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

faropénem — acide (+)-(5*R*,6*S*)-6-[(1*R*)-1-hydroxyéthyl]-7-oxo-3-[(2*R*)-tétrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique

faropenem — ácido (+)-(5*R*,6*S*)-6-[(1*R*)-1-hidroxietil]-7-oxo-3-[(2*R*)-tetrahidro-2-furil]-4-tia-1-azabiciclo[3.2.0]hept-2-en-2-carboxílico

$C_{12}H_{15}NO_5S$

fenleutonum

fenleuton — (±)-1-[3-[*m*-(*p*-fluorophenoxy)phenyl]-1-methyl-2-propynyl]-1-hydroxyurea

fenleuton — (±)-1-[(1*RS*)-3-[3-(4-fluorophénoxy)phényl]-1-méthylprop-2-ynyl]-1-hydroxyurée

fenleuton — (±)-1-[3-[*m*-(*p*-fluorofenoxi)fenil]-1-metil-2-propinil]-1-hidroxiurea

$C_{17}H_{15}FN_2O_3$

fodipirum

fodipir — *N*,*N*'-ethylenebis[*N*-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridyl]= methyl]glycine] 5,5'-bis(dihydrogenphosphate)

fodipir — *N*,*N*'-éthane-1,2-diylbis[N-[[3-hydroxy-2-méthyl-5-[(phosphonooxy)méthyl]= pyridin-4-yl]méthyl]glycine]

fodipir — *N*,*N*'-etilenbis[*N*-[[3-hidroxi-5-(hidroximetil)-2-metil-4-piridil]metil]glicina] 5,5'-bis(dihidrógenofosfato)

$C_{22}H_{32}N_4O_{14}P_2$

follitropinum alfa

follitropin alfa

follicle-stimulating hormone, glycoform α
α-subunit:
chorionic gonadotropin (human α-subunit protein moiety reduced)
β-subunit:
follicle-stimulating hormone (human clone λ 15B β-subunit protein moiety reduced)

follitropine alfa

hormone folliculo-stimulante, forme glycosylée α
Sous-unité α :
gonadotropine chorionique (partie protéique réduite de la sous-unité α humaine)
Sous-unité β :
hormone folliculo-stimulante (partie protéique réduite de la sous-unité β du clone humain λ 15B)

folitropina alfa

hormona estimulante del folículo, glicoforma α
subunidad α :
gonadotropina coriónica (fracción proteica reducida de la subunidad α humana)
subunidad β :
hormona estimulante del folículo (fracción proteica reducida de la subunidad β del clon humano humane λ 15B)

α : $C_{437}H_{682}N_{122}O_{134}S_{13}$

β : $C_{538}H_{833}N_{145}O_{171}S_{13}$

fradafibanum

fradafiban

(3*S*,5*S*)-5-[[(4'-amidino-4-biphenylyl)oxy]methyl]-2-oxo-3-pyrrolidineacetic acid

fradafiban

acide 2-[(3*S*,5*S*)-5-[[(4'-amidinobiphényl-4-yl)oxy]méthyl]-2-oxopyrrolidin-3-yl]acétique

fradafiban

àcido (3*S*,5*S*)-5-[[(4'-amidino-4-bifenilil)oxi]metil]-2-oxo-3-pirrolidinacético

$C_{20}H_{21}N_3O_4$

fuladectinum

fuladectin

a mixture of components A_4 and A_3,
component A_4 (major component):
4'-[2-[[(2a*E*,4*E*,5'*S*,6*S*,6'*R*,7*R*,8*E*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-6'-ethyl-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tetradecahydro-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxospiro[11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2'-[2*H*]pyran]-7-yl]oxy]ethyl]-*N*-methylmethanesulfonanilide
component A_3 (minor component):
4'-[2-[[(2a*E*,4*E*,5'*S*,6*S*,6'*R*,7*R*,8*E*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tetradecahydro-20,20b-dihydroxy-5',6,6',8,19-pentamethyl-17-oxospiro[11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2'-[2*H*]pyran]-7-yl]oxy]ethyl]-*N*-methylmethanesulfonanilide

fuladectine

mélange des constituants A_4 et A_3,
constituant A_4 (constituant principal):
N-[4-[2-[[(2a*E*,4*E*,8*E*)-(2'*R*,5'*S*,6*S*,6'*R*,7*R*,11*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-6'-éthyl-20,20b-dihydroxy-5',6,8,19-tétraméthyl-7-oxo-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tétradécahydrospiro[11,15-méthano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadécène-13,2'-[2*H*]pyran]-7-yl]oxy]éthyl]phényl]-*N*-méthylméthanesulfonamide
constituant A_3 (constituant secondaire):
N-[4-[2-[[(2a*E*,4*E*,8*E*)-(2'*R*,5'*S*,6*S*,6'*R*,7*R*,11*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-20,20b-dihydroxy-5',6,6',8,19-pentaméthyl-7-oxo-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tétradécahydrospiro[11,15-méthano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadécène-13,2'-[2*H*]pyran]-7-yl]oxy]éthyl]phényl]-*N*-méthylméthanesulfonamide

fuladectina

mezcla de los componentes A_4 y A_3,
componente A_4 (constituyente principal):
4'-[2-[[(2a*E*,4*E*,5'*S*,6*S*,6'*R*,7*R*,8*E*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-6'-etil-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tetradecahidro-20,20b-dihidroxi-5',6,8,19-tetrametil-17-oxospiro[11,15-metano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxaciclooctadecin-13,2'-[2*H*]piran]-7-il]oxi]etil]-*N*-metilmetanesulfonanilida
componente A_3 (constituyente segundario):
4'-[2-[[(2a*E*,4*E*,5'*S*,6*S*,6'*R*,7*R*,8*E*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tetradecahidro-20,20b-dihidroxi-5',6,6',8,19-pentametil-17-oxospiro[11,15-metano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxaciclooctadecin-13,2'-[2*H*]piran]-7-il]oxi]etil]-*N*-metilmetanesulfonanilida

A_4 : $C_{42}H_{59}NO_{10}S$ + A_3 : $C_{41}H_{57}NO_{10}S$

gadoversetamidum

gadoversetamide

[*N*,*N*-bis[2-[[(carboxymethyl)[(2-methoxyethyl)carbamoyl]methyl]amino]ethyl]=glycinato(3-)]gadolinium

gadoversétamide

[*N*,*N*-bis[2-[(carboxyméthyl)[2-[(2-méthoxyéthyl)amino]-2-oxoéthyl]amino]=éthyl]glycinato(3-)]gadolinium

gadoversetamida

[*N*,*N*-bis[2-[[(carboximetil)[(2-metoxietil)carbamoil]metil]amino]etil]=glicinato(3-)]gadolinio

$C_{20}H_{34}GdN_5O_{10}$

galdansetronum

galdansetron

(+)-(3*R*)-2,3-dihydro-9-methyl-3-[(5-methylimidazol-4-yl)methyl]carbazol-4(1*H*)-one

galdansétron

(+)-(3*R*)-9-méthyl-3-[(5-méthyl-1*H*-imidazol-4-yl)méthyl]-1,2,3,9-tétrahydro-4*H*-carbazol-4-one

galdansetron

(+)-(3*R*)-2,3-dihidro-9-metil-3-[(5-metilimidazol- 4-il)metil]carbazol-4(1*H*)-ona

$C_{18}H_{19}N_3O$

goralatidum

goralatide

1-[N^2-[*N*-(*N*-acetyl-L-seryl)-L-α-aspartyl]-L-lysyl]-L-proline

goralatide

(*N*-acétyl-L-séryl)-L-α-aspartyl-L-lysyl-L-proline

goralatida

1-[N^2-[*N*-(*N*-acetil-L-seril)-L-α-aspartil]-L-lisil]-L-prolina

$C_{20}H_{33}N_5O_9$

Idramantonum

idramantone — 5-hydroxy-2-adamantanone

idramantone — 5-hydroxytricyclo[3.3.1.1^{3,7}]décan-2-one

idramantona — 5-hidroxi-2-adamantanona

$C_{10}H_{14}O_2$

Ifetrobanum

ifetroban — *o*-[[(1*S*,2*R*,3*S*,4*R*)-3-[4-(pentylcarbamoyl)-2-oxazolyl]-7-oxabicyclo=[2.2.1]hept-2-yl]methyl]hydrocinnamic acid

ifétroban — acide 3-[2-[[(1*S*,2*R*,3*S*,4*R*)-3-[4-[(pentylamino)carbonyl]oxazol-2-yl]-7-oxa=bicyclo[2.2.1]hept-2-yl]méthyl]phényl]propanoïque

ifetroban — ácido *o*-[[(1*S*,2*R*,3*S*,4*R*)-3-[4-(pentilcarbamoil)-2-oxazolil]-7-oxabiciclo=[2.2.1]hept-2-il]metil]hidrocinámico

$C_{25}H_{32}N_2O_5$

Imidaprilatum

imidaprilat — (4*S*)-3-[(2*S*)-*N*-[(1*S*)-1-carboxy-3-phenylpropyl]alanyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid

imidaprilate — acide (*S*)-3-[(*S*)-2-[[(*S*)-1-carboxy-3-phénylpropyl]amino]propanoyl]-1-méthyl-2-oxo-imidazolidine-4-carboxylique

imidaprilat — ácido (4*S*)-3-[(2*S*)-*N*-[(1*S*)-1-carboxi-3-fenilpropil]alanil]-1-metil-2-oxo-4-imidazolidincarboxílico

$C_{18}H_{23}N_3O_6$

Imiglucerasum

imiglucerase — 495-L-histidineglucosylceramidase (human placenta isoenzyme protein moiety)

imiglucérase — [495-L-histidine]glucosylcéramidase (partie protéique d'isoenzyme de placenta humain)

imiglucerasa — 495-L-histidinaglucosilceramidasa (isoenzima de placenta humana, fracción proteica)

$C_{2532}H_{3843}N_{671}O_{711}S_{16}$

Inogatranum

inogatran — *N*-[(1*R*)-2-cyclohexyl-1-[[(2*S*)-2-[(3-guanidinopropyl)carbamoyl]piperidino]=carbonyl]ethyl]glycine

inogatran — acide 2-[[(1*R*)-1-(cyclohexylméthyl)-2-[(2*S*)-2-[[(3-guanidinopropyl)amino]=carbonyl]pipéridin-1-yl]-2-oxoéthyl]amino]acétique

inogatran — *N*-[(1*R*)-2-ciclohexil-1-[[(2*S*)-2-[(3-guanidinopropil)carbamoil]piperidino]=carbonil]etil]glicina

$C_{21}H_{38}N_6O_4$

Inolimomabum

inolimomab — immunoglobulin G 1 (mouse monoclonal B-B10 γ-chain anti-human interleukin-2 receptor α-chain), disulfide with mouse monoclonal B-B10 κ-chain, dimer

inolimomab — immunoglobuline G 1 (chaîne γ de l'anticorps monoclonal de souris B-B10 dirigé contre la chaîne α du récepteur de l'interleukine-2 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris B-B10

inolimomab	inmunoglobulina G 1 (cadena γ del anticuerpo monoclonal de ratón B-B10 anti-cadena α del receptor de interleukina-2 humana), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón B-B10
insulinum lisprum	
insulin lispro	28^{B}-L-lysine-29^{B}-L-prolineinsulin (human)
insuline lispro	[28^{B}-L-lysine-29^{B}-L-proline]insuline humaine
insulina lispro	28^{B}-L-lisina-29^{B}-L-prolinainsulina (humana)
	$C_{257}H_{383}N_{65}O_{77}S_6$
ipenoxazonum	
ipenoxazone	(+)-(4*S*,5*R*)-3-[3-(hexahydro-1*H*-azepin-1-yl)propyl]-4-isobutyl-5-phenyl-2-oxazolidinone
ipénoxazone	(+)-(4*S*,5*R*)-3-[3-(hexahydro-1*H*-azépin-1-yl)propyl]-4-(2-méthylpropyl)-5-phényloxazolidin-2-one
ipenoxazona	(+)-(4*S*,5*R*)-3-[3-(hexahidro-1*H*-azepin-1-il)propil]-4-isobutil-5-fenil-2-oxazolidinona
	$C_{22}H_{34}N_2O_2$
irbesartanum	
irbesartan	2-butyl-3-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]-1,3- diazaspiro[4 4]non-1-en-4-one
irbésartan	2-butyl-3-[4-[2-(1*H*-tétrazol-5-yl)phényl]benzyl]-1,3-diazaspiro[4.4]non-1-én-4-one
irbesartan	2-butil-3-[*p*-(*o*-1*H*-tetrazol-5-ilfenil)bencil]-1,3-diazaspiro[4.4]non-1-en-4-ona
	$C_{25}H_{28}N_6O$
itamelinum	
itameline	*p*-chlorophenyl 3-formyl-5,6-dihydro-1(2*H*)-pyridinecarboxylate, *O*-methyloxime
itaméline	(*E*)-3-[(méthoxyimino)méthyl]-5,6-dihydropyridine-1(2*H*)-carboxylate de 4-chlorophényle
itamelina	*p*-clorofenil 3-formil-5,6-dihidro-1(2*H*)-piridinacarboxilato, *O*-metiloxima
	$C_{14}H_{15}ClN_2O_3$
lamifibanum	
lamifiban	[[1-[*N*-(*p*-amidinobenzoyl)-L-tyrosyl]-4-piperidyl]oxy]acetic acid
lamifiban	acide 2-[[1-[(2*S*)-2-[(4-amidinobenzoyl)amino]-3-(4-hydroxyphényl)=propanoyl]pipéridin-4-yl]oxy]acétique
lamifiban	àcido[[1-[*N*-(*p*-amidinobenzoil)-L-tirosil]-4-piperidil]oxi] acético
	$C_{24}H_{28}N_4O_6$
lanperisonum	
lanperisone	(-)-(*R*)-2-methyl-3-(1-pyrrolidinyl)-4'-(trifluoromethyl)propiophenone
lanpérisone	(-)-(2*R*)-2-méthyl-3-(pyrrolidin-1-yl)-1-[4-(trifluorométhyl)phényl]propan-1-one
lanperisona	(-)-(*R*)-2-metil-3-(1-pirrolidinil)-4'-(trifluorometil)propiofenona
	$C_{15}H_{18}F_3NO$

lanprostonum

lanproston (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-2-[(*E*)-2-[2-[(*m*-chlorophenoxy)methyl]-1,3-dioxolan-2-yl]vinyl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid

lanprostone acide (5*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-2-[(1*E*)-2-[2-[(3-chlorophénoxy)méthyl]-1,3-dioxolan-2-yl]éthényl]-3,5-dihydroxycyclopentyl]hept-5-énoique

lanproston àcido (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-2-[(1*E*)-2-[2-[(*m*-clorofenoxi)metil]-1,3-dioxolan-2-il]vinil]-3,5-dihidroxiciclopentil]-5-heptenoico

$C_{24}H_{31}ClO_7$

lenerceptum

lenercept 1-182-tumor necrosis factor receptor (human reduced), (182→104')-protein with 104-330-immunoglobulin G 1 (human clone pTJ5 Cγ 1 reduced)

lénercept 1-182-récepteur du facteur de nécrose tumorale (humain réduit), (182→104')-protéine avec la 104-330-immunoglobuline G 1 (clone humain pTJ5 Cγ 1 réduit)

lenercept 1-182-receptor del factor de necrosis tumoral (humano reducido), (182→104')-proteína con la 104-330-inmunoglobulina G 1 (clon humano pTJ5 Cγ 1 reducido)

$C_{1993}H_{3112}N_{562}O_{624}S_{34}$

levosemotiadilum

levosemotiadil (-)-(*S*)-2-[5-methoxy-2-[3-[methyl[2-[3,4-(methylenedioxy)phenoxy]ethyl]=amino]propoxy]phenyl]-4-methyl-2*H*-1,4-benzothiazin-3(4*H*)-one

lévosémotiadil (-)-(2*S*)-2-[2-[[3-[[2-(1,3-benzodioxol-5-yloxy)éthyl]méthylamino]propyl]oxy]-5-méthoxyphényl]-4-méthyl-2*H*-1,4-benzothiazin-3(4*H*)-one

levosemotiadil (-)-(*S*)-2-[5-metoxi-2-[3-[metil[2-[3,4-(metilenodioxi)fenoxi]etil]=amino]propoxi]fenil]-4-metil-2*H*-1,4-benzotiazin-3(4*H*)-ona

$C_{29}H_{32}N_2O_6S$

lexacalcitolum

lexacalcitol (5*Z*,7*E*,20*R*)-20-[(4-ethyl-4-hydroxyhexyl)oxy]-9,10-secopregna-5,7,10(19)-triene-1α,3β-diol

lexacalcitol (5*Z*,7*E*)-(20*R*)-20-[(4-éthyl-4-hydroxyhexyl)oxy]-9,10-sécoprégna-5,7,10(19)-triène-1α,3β-diol

lexacalcitol (5*Z*,7*E*,20*R*)-20-[(4-etil-4-hidroxihexil)oxi]-9,10-secopregna-5,7,10(19)-trieno-1α,3β-diol

$C_{29}H_{48}O_4$

lirequinilum

lirequinil (3*S*)-1-[(10-chloro-6,7-dihydro-4-oxo-3-phenyl-4*H*-benzo[*a*]quinolizin-1-yl)=carbonyl]-3-ethoxypyrrolidine

liréquinil (3*S*)-1-[(10-chloro-4-oxo-3-phényl-6,7-dihydro-4*H*-benzo[*a*]quinolizin-1-yl)=carbonyl]-3-éthoxypyrrolidine

lirequinilo (3*S*)-1-[(10-cloro-6,7-dihidro-4-oxo-3-fenil-4*H*-benzo[*a*]quinolizin-1-il)=carbonil]-3-etoxipirrolidina

$C_{26}H_{25}ClN_2O_3$

lisofyllinum

lisofylline	1-[(*R*)-5-hydroxyhexyl]theobromine
lisofylline	1-[(5*R*)-5-hydroxyhexyl]-3,7-diméthyl-3,7-dihydro-1*H*-purin-2,6-dione
lisofilina	1-[(*R*)-5-hidroxihexil]teobromina
	$C_{13}H_{20}N_4O_3$

lobucavirum

lobucavir	9-[(1*R*,2*R*,3*S*)-2,3-bis(hydroxymethyl)cyclobutyl]guanine
lobucavir	2-amino-9-[(1*R*,2*R*,3*S*)-2,3-bis(hydroxyméthyl)cyclobutyl]-1,9-dihydro-6*H*-purin-6-one
lobucavir	9-[(1*R*,2*R*,3*S*)-2,3-bis(hidroximetil)ciclobutil]guanina
	$C_{11}H_{15}N_5O_3$

lutropinum alfa

lutropin alfa	luteinizing hormone (human α-subunit reduced complex human β-subunit reduced), glycoform α α-subunit: chorionic gonadotropin (human α-subunit protein moiety reduced) β-subunit: luteinizing homone (human β-subunit protein moiety reduced)
lutropine alfa	hormone lutéinisante (complexe de sous-unités α humaine réduite et de sous-unité β humaine réduite), forme glycosylée α Sous-unité α : gonadotropine chorionique (partie protéique réduite de la sous-unité α humaine) Sous-unité β : hormone lutéinisante (partie protéique réduite de la sous-unité β humaine)
lutropina alfa	hormona luteinizante (complejo de los subunidadas α humana reducida y β humana reducida), glicoforma α subunidad α : gonadotropina coriónica (fracción proteica reducida de la subunidad α humana) subunidad β : hormona luteinizante (fracción proteica reducida de la subunidad β humana)
	α : $C_{437}H_{682}N_{122}O_{134}S_{13}$ + β : $C_{577}H_{929}N_{165}O_{161}S_{14}$

mangafodipirum

mangafodipir	hexahydrogen (*OC*-6-13)-[[*N*,*N*'-ethylenebis[*N*-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridyl]methyl]glycine] 5,5'-bis(phosphato)](8-)] manganate(6-)
mangafodipir	(*OC*-6-13)-hexahydrogéno[[*N*,*N*'-ethane-1,2-diylbis[*N*-[[3-hydroxy-2-méthyl-5-[(phosphonooxy)méthyl]pyridin-4-yl]méthyl]glycinato](8-)]manganate(6-)]
mangafodipir	hexahidrógeno (*OC*-6-13)-[*N*,*N*'-etilenbis[*N*-[[3-hidroxi-5-(hidroximetil)-2-metil-4-piridil]metil]glicina] 5,5'-bis(fosfato)](8-)]manganato(6-)
	$C_{22}H_{30}MnN_4O_{14}P_2$

mapinastinum

mapinastine — 1-(2-ethoxyethyl)-2-[[4-(4-pyrazol-1-ylbutyl)-1-piperazinyl]methyl]= benzimidazole

mapinastine — 1-(2-éthoxyéthyl)-2-[[4-[4-(1*H*-pyrazol-1-yl)butyl]pipérazin-1-yl]méthyl]-1*H*-benzimidazole

mapinastina — 1-(2-etoxietil)-2-[[4-(4-pirazol-1-ilbutil)-1-piperazinil]metil]bencimidazol

$C_{23}H_{34}N_6O$

mazapertinum

mazapertine — 1-[α-[4-(*o*-isopropoxyphenyl)-1-piperazinyl]-*m*-toluoyl]piperidine

mazapertine — 1-[3-[[4-[2-(1-méthyléthoxy)phényl]pipérazin-1-yl]méthyl]benzoyl]pipéridine

mazapertina — 1-[α-[4-(*o*-isopropoxifenil)-1-piperazinil]-*m*-toluoil]piperidina

$C_{26}H_{35}N_3O_2$

mibefradilum

mibefradil — (1*S*,2*S*)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1- isopropyl-2-naphthyl methoxyacetate

mibéfradil — 2-méthoxyacétate de (1*S*,2*S*)-2-[2-[[3-(1*H*-benzimidazol-2-yl)propyl]méthyl= amino]éthyl]-6-fluoro-1-(1-méthyléthyl)-1,2,3,4-tétrahydronaphtalén-2-yle

mibefradil — (1*S*,2*S*)-2-[2-[[3-(2-bencimidazolil)propil]metilamino]etil]-6-fluoro-1,2,3,4-tetrahidro-1-isopropil-2-naftil metoxiacetato

$C_{29}H_{38}FN_3O_3$

mirisetronum

mirisetron — 1-cyclohexyl-1,4-dihydro-4-oxo-*N*-1α*H*,5α*H*-tropan-3α-yl-3-quinoline= carboxamide

mirisétron — 1-cyclohexyl-*N*-[(1*R*,3*r*,5*S*)-8-méthyl-8-azabicyclo[3.2.1]oct-3-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxamide

mirisetron — 1-ciclohexil-1,4-dihidro-4-oxo-*N*-1αH,5αH-tropan-3α-il-3-quinolina= carboxamida

$C_{24}H_{31}N_3O_2$

mobenakinum

mobenakin — 71-L-serineinterleukin 1β (human clone pIL-1-14 reduced)

mobénakine — [71-L-sérine]interleukine 1β (clone humain pIL-1-14, réduite)

mobenakina — 71-L-serinainterleuquina 1β (clon humano pIL-1-14 reducido)

$C_{773}H_{1219}N_{201}O_{238}S_7$

monteplasum

monteplase — 84-L-serineplasminogen activator (human tissue-type 2-chain form), cyclic (6→36), (32'→48'), (34→43), (40'→109'), (51→73), (56→62), (75→83), (92→173), (113→155), (120'→ 264), (134'→209'), (144→168), (166'→182'), (180→261), (199'→227'), (201→243), (232→256)-heptadecakis(disulfide)

montéplase — (6→36), (32'→48'), (34→43), (40'→109'), (51→73), (56→62), (75→83), (92→173), (113→155), (120'→ 264), (134'→209'), (144→168), (166'→182'), (180→261), (199'→227'), (201→243), (232→256)-heptadécakis(disulfure cyclique) du 84-L-sérine(activateur du plasminogène, humain, de type tissulaire, constitué de deux châines)

monteplasa — 84-L-serina activador del plasminógeno (tipo tisular humano forma bicatenaria), (6→36), (32'→48'), (34→43), (40'→109'), (51→73), (56→62), (75→83), (92→173), (113→155), (120'→ 264), (134'→209'), (144→168), (166'→182'), (180→261), (199'→227'), (201→243), (232→256)-heptadecakis(disulfuro cíclico)

$C_{2569}H_{3896}N_{746}O_{783}S_{39}$

moroctocogum alfa

moroctocog alfa — (1-742)-(1637-1648)-blood-coagulation factor VIII (human reduced) complex with 1649-2332-blood-coagulation factor VIII (human reduced)

moroctocog alfa — complexe du (1-742)-(1637-1648)-facteur VIII de coagulation sanguine (humain réduit) avec le 1649-2332-facteur VIII de coagulation sanguine (humain réduit)

moroctocog alfa — (1-742)-(1637-1648)-factor de coagulación VIII (humano reducido) compleso con 1649-2332-factor de coagulación VIII (humano reducido)

$C_{3953}H_{6020}N_{1040}O_{1158}S_{29}$ + $C_{3553}H_{5412}N_{956}O_{1028}S_{33}$

muplestimum

muplestim — interleukin 3 (human protein moiety reduced)

muplestim — interleukine 3 (partie protéique humaine réduite)

muplestim — interleukina 3 (fracción proteica reducida humana)

$C_{670}H_{1076}N_{186}O_{199}S_5$

nacolomabum tafenatoxum

nacolomab tafenatox — 20-244-immunoglobulin G 1 (mouse monoclonal r-C242Fab-SEA clone pKP941 Fab fragment γ-chain anti-human colorectal tumor antigen C242) (244→ 1')-protein with enterotoxin A (*Staphyloccoccus aureus*), disulfide with mouse monoclonal r-C242Fab-SEA clone pKP941 κ-chain

nacolomab tafénatox — 20-244-immunoglobuline G1 (chaîne γ du fragment Fab de l'anticorps monoclonal de souris r-C242Fab-SEA, clone pKP941, anti-antigène C242 de tumeur colorectale humaine) (244→ 1')-protéine avec l'entérotoxine A (*Staphylococcus aureus*), disulfure avec la chaîne κ de l'anticorps monoclonal de souris r-C242Fab-SEA, clone pKP941

nacolomab tafenatox — 20-244-inmunoglobulina G 1 (cadena γ del fragmento Fab del anticuerpo monoclonal de ratón r-C242Fab-SEA, clon pKP941, antiantígeno C 242 de tumor colorrectal humano) (244→1)-proteina con la enterotoxina A (*Staphyloccoccus aureus*), disulfuro con la cadena κ del anticuerpo monoclonal de ratón r-C242Fab-SEA, clon pKP941

napsagatranum

napsagatran — *N*-[*N*^{4}-[[(3*S*)-1-amidino-3-piperidyl]methyl]-*N*^{2}-(2-naphthylsulfonyl)-L-asparaginyl]-*N*-cyclopropylglycine

napsagatran — acide 2-[[(2*S*)-4-[[[(3*S*)-1-amidinopipéridin-3-yl]méthyl]amino]-2-[[(naphtalén-2-yl)sulfonyl]amino]-4-oxobutanoyl](cyclopropyl)amino]acétique

napsagatran — *N*-[*N*^{4}-[[(3*S*)-1-amidino-3-piperidil]metil]-*N*^{2}-(2-naftilsulfonil)-L-asparraginil]-*N*-ciclopropilglicina

$C_{26}H_{34}N_6O_6S$

nemorubicinum

nemorubicin — (1*S*,3*S*)-3-glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 2,3,6-trideoxy-3-[(*S*)-2-methoxymorpholino]-α-L-*lyxo*-hexopyranoside

némorubicine — (8*S*,10*S*)-6,8,11-trihydroxy-8-(2-hydroxyacétyl)-1-méthoxy-10-[[3-[(2*S*)-2-méthoxymorpholin-4-yl]-2,3,6-tridésoxy-α-L-*lyxo*-hexopyranosyl]oxy]-7,8,9,10-tétrahydronaphtacène-5,12-dione

nemorubicina — (1*S*,3*S*)-3-glicoloil-1,2,3,4,6,11-hexahidro-3,5,12-trihidroxi-10-metoxi-6,11-dioxo-1-naftacenil 2,3,6-tridesoxi-3-[(*S*)-2-metoximorfolino]-α-L-*lixo*-hexopiranósido

$C_{32}H_{37}NO_{13}$

netivudinum

netivudine — 1-β-D-arabinofuranosyl-5-(1-propynyl)uracil

nétivudine — 1-(β-D-arabinofuranosyl)-5-(prop-1-ynyl)pyrimidine-2,4(1*H*,3*H*)-dione

netivudina — 1-β-D-arabinofuranosil-5-(1-propinil)uracilo

$C_{12}H_{14}N_2O_6$

nicanartinum

nicanartine — 2,6-di-*tert*-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol

nicanartine — 2,6-bis(1,1-diméthyléthyl)-4-[3-[(pyridin-3-yl)méthoxy]propyl]phénol

nicanartina — 2,6-di-*terc*-butil-4-[3-(3-piridilmetoxi)propil]fenol

$C_{23}H_{33}NO_2$

ocinaplonum

ocinaplon — 2-pyridyl 7-(4-pyridyl)pyrazolo[1,5-*a*]pyrimidin-3-yl ketone

ocinaplone — (pyridin-2-yl)[7-(pyridin-4-yl)pyrazolo[1,5-*a*]pyrimidin-3-yl]méthanone

ocinaplon — 2-piridil 7-(4-piridil)pirazolo[1,5-*a*]pirimidin-3-il cetona

$C_{17}H_{11}N_5O$

olopatadinum

olopatadine — 11-[(*Z*)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[*b*,*e*]oxepin-2-acetic acid

olopatadine — acide 2-[11-[(1*Z*)-3-(diméthylamino)propylidène]-6,11-dihydrodibenzo=[*b*,*e*]oxépin-2-yl]acétique

olopatadina — ácido 11-[(*Z*)-3-(dimetilamino)propiliden]-6,11-dihidrodibenz[*b*,*e*]oxepin-2-acético

$C_{21}H_{23}NO_3$

ontazolastum

ontazolast — 2-[[(*S*)-2-cyclohexyl-1-(2-pyridyl)ethyl]amino]-5-methylbenzoxazole

ontazolast — [(1*S*)-2-cyclohexyl-1-(pyridin-2-yl)éthyl](5-méthylbenzoxazol-2-yl)amine

ontazolast — 2-[[(*S*)-2-ciclohexil-1-(2-piridil)etil]amino]-5-metilbenzoxazol

$C_{21}H_{25}N_3O$

orientiparcinum

orientiparcin — a mixture of orienticine A and orienticine D,
orienticine A (major component):
(-)-(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-22-[(3-amino-2,3,6-trideoxy-3-*C*-methyl-α-L-*arabino*-hexopyranosyl)oxy]-44-[[2-*O*-(3-amino-2,3,6-trideoxy-3-*C*-methyl-α-L-*arabino*-hexopyranosyl)-β-D-glucopyranosyl]oxy]-3-(carbamoylmethyl)-19-chloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,28,30,32-tetrahydroxy-6-[(2*R*)-4-methyl-2-(methylamino)valeramido-2,5,24,38,39-pentaoxo-22*H*-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1*H*,16*H*-[1,6,9]oxadiazacyclohexadecino[4,5-*m*][10,2,16]benzoxadiaza=cyclotetracosine-26-carboxylic acid
orienticine D (minor component) :
(-)-(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-22-[(3-amino-2,3,6-trideoxy-3-*C*-methyl-α-L-*arabino*-hexopyranosyl)oxy]-44-[[2-*O*-(3-amino-2,3,6-trideoxy-3-*C*-methyl-α-L-*arabino*-hexopyranosyl)-β-D-glucopyranosyl]oxy]-3-(carbamoylmethyl)-19-chloro-6-[(2*R*)-2-(dimethylamino)-4-methylvaleramido]-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,28,30,32-tetrahydroxy-2,5,24,38,39-pentaoxo-22*H*-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1*H*,16*H*-[1,6,9]oxadiazacyclohexadecino[4,5-*m*][10,2,16]benzoxadiaza=cyclotetracosine-26-carboxylic acid

orientiparcine — mélange d'orienticine A et d'orienticine D,
orienticine A (constituant principal):
acide (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-22-[(3-amino-3-*C*-méthyl-2,3,6-tridésoxy-α-L-*arabino*-hexopyranosyl)oxy]-44-[[2-*O*-(3-amino-3-*C*-méthyl-2,3,6-tridésoxy-α-L-*arabino*-hexopyranosyl)-β-D-glucopyranosyl]oxy]-3-(carbamoylméthyl)-19-chloro-7,28,30,32-tétrahydroxy-6-[[(*R*)-4-méthyl-2-(méthylamino)pentanoyl]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tétradécahydro-8,11:18,21-diéthéno-23,36-(iminométhano)-22*H*-13,16:31,35-diméthéno-1*H*,13*H*-[1,6,9]oxadiazacyclohexadécino[4,5-*m*][10,2,16]benzoxadiaza=cyclotétracosène-26-carboxylique
orienticine D (constituant secondaire):
acide (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-22-[(3-amino-3-*C*-méthyl-2,3,6-tridésoxy-α-L-*arabino*-hexopyranosyl)oxy]-44-[[2-*O*-(3-amino-3-*C*-méthyl-2,3,6-tridésoxy-α-L-*arabino*-hexopyranosyl)-β-D-glucopyranosyl]oxy]-3-(carbamoylméthyl)-19-chloro-7,28,30,32-tétrahydroxy-6-[[(*R*)-2-(diméthylamino)-4-méthylpentanoyl]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tétradécahydro-8,11:18,21-diéthéno-23,36-(iminométhano)-22*H*-13,16:31,35-diméthéno-1*H*,13*H*-[1,6,9]oxadiazacyclohexadécino[4,5-*m*][10,2,16]benzoxadiaza=cyclotétracosène-26-carboxylique

orientiparcina

mezcla de orienticina A y de orienticina D,
orienticina A (constituyente principal):
ácido (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-22-[(3-amino-3-*C*-metil-2,3,6-tridesoxi-α-L-*arabino*-hexopiranosil)oxi]-44-[[2-*O*-(3-amino-3-*C*-metil-2,3,6-tridesoxi-α-L-*arabino*-hexopiranosil)-β-D-glucopiranosil]oxi]-3-(carbamoilmetil)-19-cloro-7,28,30,32-tetrahidroxi-6-[[(*R*)-4-metil-2-(metilamino)pentanoil]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahidro-8,11:18,21-dieteno-23,36-(iminometano)-22*H*-13,16:31,35-dimeteno-1*H*,13*H*-[1,6,9]oxadiazaciclohexadecino[4,5-*m*][10,2,16]=benzoxadiazaciclotetracoseno-26-carboxílico
orienticina D (constituyente secundario):
ácido (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-22-[(3-amino-3-*C*-metil-2,3,6-tridesoxi-α-L-*arabino*-hexopiranosil)oxi]-44-[[2-*O*-(3-amino-3-*C*-metil-2,3,6-tridesoxi-α-L-*arabino*-hexopiranosil)-β-D-glucopiranosil]oxi]-3-(carbamoilmetil)-19-cloro-7,28,30,32-tetrahidroxi-6-[[(*R*)-2-(dimetilamino)-4-metilpentanoil]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahidro-8,11:18,21-dieteno-23,36-(iminometano)-22*H*-13,16:31,35-dimeteno-1*H*,13*H*-[1,6,9]oxadiaza=ciclohexadecino[4,5-*m*][10,2,16]benzoxadiazaciclotetracoseno-26-carboxílico

A: $C_{73}H_{89}ClN_{10}O_{26}$ + D: $C_{74}H_{91}ClN_{10}O_{26}$

paclitaxelum

paclitaxel

(2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5*H*-cyclodeca[3,4]benz[1,2-*b*]oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2*R*,3*S*)-*N*-benzoyl-3-phenylisoserine

paclitaxel

(2*R*,3*S*)-3-(benzoylamino)-2-hydroxy-3-phénylpropanoate de (2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-6,12b-bis(acétyloxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tétraméthyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodécahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxét-9-yle

paclitaxel

(2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahidro-4,6,9,11,12,12b-hexahidroxi-4a,8,13,13-tetrametil-7,11-metano-5*H*-ciclodeca[3,4]benz[1,2-*b*]oxet-5-ona 6,12b-diacetato, 12-benzoato, 9-ester con (2*R*,3*S*)-*N*-benzoil-3-fenilisoserina

$C_{47}H_{51}NO_{14}$

pazufloxacinum

pazufloxacin

(-)-(3*S*)-10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid

pazufloxacine

acide (-)-(3*S*)-10-(1-aminocyclopropyl)-9-fluoro-3-méthyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylique

pazufloxacino

ácido (-)-(3*S*)-10-(1-aminociclopropil)-9-fluoro-2,3-dihidro-3-metil-7-oxo-7*H*-pirido[1,2,3-*de*]-1,4-benzoxazina-6-carboxílico

$C_{16}H_{15}FN_2O_4$

pegorgoteinum

pegorgotein — superoxide dismutase, reaction product with succinic anhydride, esters with polyethylene glycol monomethyl ether

pégorgotéine — esters du produit de réaction de l'anhydride succinique sur la superoxyde dismutase et de monoéther méthylique de polyéthylèneglycol

pegorgotein — esteres del producto de reacción del anhidrido succínico con la superoxido dismutasa y del monoeter metílico del polietilenglicol

perospironum

perospirone — *cis*-*N*-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cyclohexane=dicarboximide

pérospirone — *cis*-2-[4-[4-(1,2-benzisothiazol-3-yl)pipérazin-1-yl]butyl]hexahydro-2*H*-isoindole-1,3-dione

perospirona — *cis*-*N*-[4-[4-(1,2-bencisotiazol-3-il)-1-piperazinil]butil]-1,2-ciclohexano=dicarboximida

$C_{23}H_{30}N_4O_2S$

pimilprostum

pimilprost — (+)-methyl [2-[(2*R*,3a*S*,4*R*,5*R*,6a*S*)-octahydro-5-hydroxy-4-[(1*E*,3*S*,5*S*)-3-hydroxy-5-methyl-1-nonenyl]-2-pentalenyl]ethoxy]acetate

pimilprost — (+)-2-[2-[(2*R*,3a*S*,4*R*,5*R*,6a*S*)-5-hydroxy-4-[(*E*)-(3*S*,5*S*)-3-hydroxy-5-méthylnon-1-ényl]octahydropentalén-2-yl]éthoxy]acétate de méthyle

pimilprost — (+)-2-[2-[(2*R*,3a*S*,4*R*,5*R*,6a*S*)-5-hidroxi-4-[(*E*)-(3*S*,5*S*)-3-hidroxi-5-metilnon-1-enil]octahidropentalen-2-il]etoxi]acetato de metilo

$C_{23}H_{40}O_5$

premafloxacinum

premafloxacin — 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(3*R*)-3-[(1*S*)-1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid

prémafloxacine — acide 1-cyclopropyl-6-fluoro-8-méthoxy-7-[(3*R*)-3-[(1*S*)-1-(méthylamino)=éthyl]pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

premafloxacino — àcido 1-ciclopropil-6-fluoro-1,4-dihidro-8-metoxi-7-[(3R)-3-[(1S)-1-(metilamino)etil]-1-pirrolidinil]-4-oxo-3-quinolincarboxílico

$C_{21}H_{26}FN_3O_4$

priliximabum

priliximab — immunoglobulin G 1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412 κ-chain, dimer

priliximab — immunoglobuline G1 (anticorps monoclonal homme-souris cm-T412 anti-antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal homme-souris cm-T412

priliximab — inmunoglobulina G 1 (anticuerpo monoclonal hombre-ratón cm-T412 anti-antígeno CD 4 humano),dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón cm-T412

prulifloxacinum

prulifloxacin (±)-7-[4-[(*Z*)-2,3-dihydroxy-2-butenyl]-1-piperazinyl]-6-fluoro-1-methyl-4-oxo-1*H*,4*H*-[1,3]thiazeto[3,2-*a*]quinoline-3-carboxylic acid, cyclic carbonate

prulifloxacine acide (±)-(1*RS*)-6-fluoro-1-méthyl-7-[4-[(5-méthyl-2-oxo-1,3-dioxol-4-yl)=méthyl]pipérazin-1-yl]-4-oxo-4*H*-[1,3]thiazéto[3,2-*a*]quinoléine-3-carboxylique

prulifloxacino ácido (±)-7-[4-[(*Z*)-2,3-dihidroxi-2-butenil]-1-piperazinil]-6-fluoro-1-metil-4-oxo-1*H*,4*H*-[1,3]tiazeto[3,2-*a*]quinolina-3-carboxílico, carbonato cíclico

$C_{21}H_{20}FN_3O_6S$

quiflaponum

quiflapon 3-(*tert*-butylthio)-1-(*p*-chlorobenzyl)-α,α-dimethyl-5-(2-quinolylmethoxy)=indole-2-propionic acid

quiflapon acide 3-[1-(4-chlorobenzyl)-3-[(1,1-diméthyléthyl)thio]-5-[(quinoléin-2-yl)=méthoxy]-1*H*-indol-2-yl]-2,2-diméthylpropanoïque

quiflapon àcido 3-(*terc*-butiltio)-1-(*p*-clorobencil)-α,α-dimetil-5-(2-quinolilmetoxi)indol-2-propiónico

$C_{34}H_{35}ClN_2O_3S$

regavirumabum

regavirumab immunoglobulin G 1 (human monoclonal γ-chain anti-human cytomegalovirus glycoprotein B), disulfide with human monoclonal κ-chain, dimer

régavirumab immunoglobuline G1 (chaîne γ de l'anticorps monoclonal humain anti-glycoprotéine B de cytomégalovirus humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain

regavirumab inmunoglobulina G 1 (cadena γ del anticuerpo monoclonal humano antiglicoproteina B de Citomegalovirus humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humano

rocepafantum

rocepafant 6-(*o*-chlorophenyl)-7,10-dihydro-1-methylthio-4*H*-pyrido[4',3':4,5]thieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepine-9(8*H*)-carboxy-*p*-anisidide

rocépafant 6-(2-chlorophényl)-*N*-(4-méthoxyphényl)-1-méthyl-7,10-dihydro-4*H*-pyrido=[4',3':4,5]thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépine-9(8*H*)-carbothioamide

rocepafant 6-(*o*-clorofenil)-7,10-dihidro-1-metiltio-4*H*-pirido[4',3' :4,5]tieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepina-9(8*H*)-carboxi-*p*-anisidida

$C_{26}H_{23}ClN_6OS_2$

rofleponidum

rofleponide 6α,9-difluoro-11β,16 α,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic (*R*)-16,17-acetal with butyraldehyde

roflépónide 16α,17-[(1*R*)-butylidènedioxy]-6α,9-difluoro-11β,21-dihydroxyprég-4-ène-3,20-dione

rofleponida 6α,9-difluoro-11β,16α,17,21-tetrahidroxipregn-4-eno-3,20-diona,(*R*)-16,17-acetal cíclico con butiraldehído

$C_{25}H_{34}F_2O_6$

ruzadolanum

ruzadolane 3-[[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl] thio]-*s*-triazolo[4,3-*a*]pyridine

ruzadolane 3-[[2-[4-(2,4-difluorophényl)pipérazin-1-yl]éthyl]thio]-1,2,4-triazolo[4,3-*a*]pyridine

ruzadolano 3-[[2-[4-(2,4-difluorofenil)-1-piperazinil]etil]tio]-*s*-triazolo[4,3-*a*]piridina

$C_{18}H_{19}F_2N_5S$

samixogrelum

samixogrel (*E*)-6-[*p*-[2-(*p*-chlorobenzenesulfonamido)ethyl]phenyl]-6-(3-pyridyl)-5-hexenoic acid

samixogrel acide (5*E*)-6-[4-[2-[[(4-chlorophényl)sulfonyl]amino]éthyl]phényl]-6-(pyridin-3-yl)hex-5-énoïque

samixogrel ácido(*E*)-6-[*p*-[2-(*p*-clorobencensulfonamido)etil]fenil]-6-(3-piridil)-5-hexenoico

$C_{25}H_{25}ClN_2O_4S$

sanfetrinemum

sanfetrinem (1*S*,5*S*,8a*S*,8b*R*)-1,2,5,6,7,8,8a,8b-octahydro-1-[(*R*)-1-hydroxyethyl]-5-methoxy-2-oxoazeto[2,1-*a*]isoindole-4-carboxylic acid

sanfétrinem acide (1*S*,5*S*,8a*S*,8b*R*)-1-[(1*R*)-1-hydroxyéthyl]-5-méthoxy-2-oxo-1,2,5,6,7,8,8a,8b-octahydroazéto[2,1-*a*]iso-indole-4-carboxylique

sanfetrinem àcido(1*S*,5*S*,8a*S*,8b*R*)-1,2,5,6,7,8,8a,8b-octahidro-1-[(*R*)-1-hidroxietil]-5-metoxi-2-oxoazeto[2,1-*a*]isoindol-4-carboxílico

$C_{14}H_{19}NO_5$

saprisartanum

saprisartan 1-[[3-bromo-2-[*o*-(1,1,1-trifluoromethanesulfonamido)phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethylimidazole-5-carboxamide

saprisartan 1-[[3-bromo-2-[2-[[(trifluorométhyl)sulfonyl]amino]phényl]benzofuran-5-yl]méthyl]-4-cyclopropyl-2-éthyl-1*H*-imidazole-5-carboxamide

saprisartan 1-[[3-bromo-2-[*o*-(1,1,1-trifluorometansulfonamido)fenil]-5-benzofuranil]metil]-4-ciclopropil-2-etilimidazol-5-carboxamida

$C_{25}H_{22}BrF_3N_4O_4S$

seprilosum

seprilose 3-*O*-heptyl-1,2-*O*-isopropylidene-α-D-glucofuranose

séprilose 3-*O*-heptyl-1,2-*O*-(1-méthyléthylidène)-α-D-glucofuranose

sepnlosa 3-*O*-heptil-1,2-*O*-isopropiliden-α-D-glucofuranosa

$C_{16}H_{30}O_6$

setipafantum

setipafant 6-(*o*-chlorophenyl)-7,10-dihydro-1-methyl-4*H*-pyrido[4',3':4,5]thieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepine-9(8*H*)-carbox-*p*-anisidide

sétipafant 6-(2-chlorophényl)-*N*-(4-méthoxyphényl)-1-méthyl-7,10-dihydro-4*H*-pyrido=[4',3':4,5]thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépine-9(8*H*)-carboxamide

setipafant 6-(*o*-clorofenil)-7,10-dihidro-1-metil-4*H*-pirido[4',3':4,5]tieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepina-9(8*H*)-carboxi-*p*-anisidida

$C_{26}H_{23}ClN_6O_2S$

tagorizinum

tagorizine (*E*)-*N*-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-6-methyl-3-pyridine= acrylamide

tagorizine (2*E*)-*N*-[4-[4-(diphénylméthyl)pipérazin-1-yl]butyl]-3-(6-méthylpyridin-3-yl)prop-2-énamide

tagorizina (*E*)-*N*-[4-[4-(difenilmetil)-1-piperazinil]butil]-6-metil-3-piridinacrilamida

$C_{30}H_{36}N_4O$

talsaclidinum

talsaclidine (3*R*)-3-(2-propynyloxy)quinuclidine

talsaclidine (3*R*)-3-(prop-2-ynyloxy)-1-azabicyclo[2.2.2]octane

talsaclidina (3*R*)-3-(2-propiniloxi)quinuclidina

$C_{10}H_{15}NO$

tasosartanum

tasosartan 5,8-dihydro-2,4-dimethyl-8-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]pyrido=[2,3-*d*]pyrimidin-7(6*H*)-one

tasosartan 2,4-diméthyl-8-[4-[2-(1*H*-tétrazol-5-yl)phényl]benzyl]-5,8-dihydro=pyrido[2,3-*d*]pyrimidin-7(6*H*)-one

tasosartan 5,8-dihidro-2,4-dimetil-8-[*p*-(*o*-1*H*-tetrazol-5-ilfenil)bencil]pirido=[2,3-*d*]pirimidin-7(6*H*)-ona

$C_{23}H_{21}N_7O$

tazarotenum

tazarotene ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate

tazarotène 6-[2-(4,4-diméthyl-3,4-dihydro-2*H*-1-benzothiin-6-yl)éthynyl]pyridine-3-carboxylate d'éthyle

tazaroteno 6-[(4,4-dimetiltiocroman-6-il)etinil]nicotinato de etilo

$C_{21}H_{21}NO_2S$

teverelixum

teverelix *N*-acetyl-3-(2-naphthyl)-D-alanyl-*p*-chloro-L-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N^6-carbamoyl-D-lysyl-L-leucyl-N^6-isopropyl-L-lysyl-L-prolyl-D-alaninamide

tévérélix [*N*-acétyl-3-(naphtalén-2-yl)-D-alanyl]-(4-chloro-L-phénylalanyl)-[3-(pyridin-3-yl)-D-alanyl]-L-séryl-L-tyrosyl-[N^6-(aminocarbonyl)-D-lysyl]-L-leucyl-[N^6-(1-méthyléthyl)-L-lysyl]-L-prolyl-D-alaninamide

teverelix [*N*-acetil-3-(naftalen-2-il)-D-alanil]-(4-cloro-L-fenilalanil)-[3-(piridin-3-il)-D-alanil]-L-seril-L-tirosil-[N^6-(aminocarbonil)-D-lisil]-L-leucil-[N^6-(1-metiletil)-L-lisil]-L-prolil-D-alaninamida

$C_{74}H_{100}ClN_{15}O_{14}$

toborinonum

toborinone (±)-6-[2-hydroxy-3-(veratrylamino)propoxy]carbostyril

toborinone (±)-6-[[(2*RS*)-3-[(3,4-diméthoxybenzyl)amino]-2-hydroxypropyl]oxy]quinoléin-2(1*H*)-one

toborinona (±)-6-[2-hidroxi-3-(veratrilamino)propoxi]carbostiril

$C_{21}H_{24}N_2O_5$

vedaprofenum

vedaprofen — (±)-4-cyclohexyl-α-methyl-1-naphthaleneacetic acid

védaprofène — acide (*RS*)-2-(4-cyclohexylnaphtalén-1-yl)propanoïque

vedaprofeno — àcido (±)-4-ciclohexil-α-metil-1-naftalenacético

$C_{19}H_{22}O_2$

versetamidum

versetamide — *N,N*-bis[2-[[(carboxymethyl)[(2-methoxyethyl)carbamoyl]methyl]amino]ethyl]= glycine

versétamide — *N,N*-bis[2-[(carboxyméthyl)[2-[(2-méthoxyéthyl)amino]-2-oxoéthyl]amino]= éthyl]glycine

versetamida — *N,N*-bis[2-[[(carboximetil)[(2-metoxietil)carbamoil]metil]amino]etil]glicina

$C_{20}H_{37}N_5O_{10}$

verteporfinum

verteporfin — a mixture (50:50) of : (±)-*trans*-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23*H*,25*H*-benzo[*b*]porphine-9,13-dipropionic acid, 3,4,9-trimethyl ester and (±)-*trans*-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23*H*,25*H*-benzo[*b*]porphine-9,13-dipropionic acid, 3,4,13-trimethyl ester

vertéporfine — mélange sensiblement équimoléculaire : d'acide 3-[(±)-*trans*-18-éthényl-3,4-bis(méthoxycarbonyl)-13-[2-(méthoxycarbonyl)éthyl]-4a,8,14,19-tétraméthyl-4,4a-dihydro-23*H*,25*H*-benzo[*b*]porphyrin-9-yl]propanoïque et d'acide 3-[(±)-*trans*-18-éthényl-3,4-bis(méthoxycarbonyl)-9-[2-(méthoxycarbonyl)éthyl]-4a,8,14,19-tétraméthyl-4,4a-dihydro-23*H*,25*H*-benzo[*b*]porphyrin-13-yl]propanoïque

verteporfina — mezcla (50:50) del : 3,4,9-trimetil ester del ácido (±)-*trans*-3,4-dicarboxi-4,4a-dihidro-4a,8,14,19-tetrametil-18-vinil-23*H*,25*H*-benzo[*b*]porfina-9,13-dipropiónico, con el 3,4,13-trimetil ester del ácido (±)-*trans*-3,4-dicarboxi-4,4a-dihidro-4a,8,14,19-tetrametil-18-vinil-23*H*,25*H*-benzo[*b*]porfina-9,13-dipropiónico

$C_{41}H_{42}N_4O_8$

zafirlukastum

zafirlukast — cyclopentyl 3-[2-methoxy-4-[(*o*-tolylsulfonyl) carbamoyl]benzyl]-1-methylindole-5-carbamate

zafirlukast — [3-[2-méthoxy-4-[[[(2-méthylphényl)sulfonyl]amino]carbonyl]benzyl]-1-méthyl-1*H*-indol-5-yl]carbamate de cyclopentyle

zafirlukast — ciclopentil 3-[2-metoxi-4-[(*o*-tolilsulfonil)carbamoil]bencil]-1-metilindol-5-carbamato

$C_{31}H_{33}N_3O_6S$

zaleplonum

zaleplon — 3'-(3-cyanopyrazolo[1,5-*a*]pyrimidin-7-yl)-*N*-ethylacetanilide

zaléplone — *N*-[3-(3-cyanopyrazolo[1,5-*a*]pyrimidin-7-y)phényl]-*N*-éthylacétamide

zaleplon — 3'-(3-cianopirazolo[1,5-*a*]pirimidin-7-il)-*N*-etilacetanilida

$C_{17}H_{15}N_5O$

zifrosilonum

zifrosilone	2,2,2-trifluoro-3'-(trimethylsilyl)acetophenone
zifrosilone	2,2,2-trifluoro-1-[3-(triméthylsilyl)phényl]éthanone
zifrosilona	2,2,2-trifluoro-3'-(trimetilsilil)acetofenona
	$C_{11}H_{13}F_3OSi$

ziprasidonum

ziprasidone	5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-2-indolinone
ziprasidone	5-[2-[4-(1,2-benzisothiazol-3-yl)pipérazin-1-yl]éthyl]-6-chloro-1,3-dihydro-2*H*-indol-2-one
ziprasidona	5-[2-[4-(1,2-bencisotiazol-3-il)-1-piperazinil]etil]-6-cloro-2-indolinona
	$C_{21}H_{21}ClN_4OS$

zucapsaicinum

zucapsaicin	(*Z*)-8-methyl-*N*-vanillyl-6-nonenamide
zucapsaïcine	(*Z*)-*N*-(4-hydroxy-3-méthoxybenzyl)-8-méthylnon-6-énamide
zucapsaicina	(*Z*)-8-metil-*N*-vanilil-6-nonenamida
	$C_{18}H_{27}NO_3$

AMENDMENTS TO PREVIOUS LISTS

WHO Drug Information, Vol. 1, No. 4, 1987

Recommended International Nonproprietary Names (Rec. INN): List 27

p. 4	ebrotidinum	*replace the chemical name by the following:*
	ebrotidine	*p*-bromo-*N*-[(*E*)-[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]=thio]ethyl]amino]methylene]benzenesulfonamide

WHO Drug Information, Vol. 3, No. 3, 1989

Recommended International Nonproprietary Names (Rec. INN): List 29

p. 2	alteplasum	*replace the description and the molecular formula by the following:*
	alteplase	plasminogen activator (human tissue-type protein moiety), glycoform α $C_{2569}H_{3894}N_{746}O_{781}S_{40}$

WHO Drug Information, Vol. 4, No. 3, 1990

Recommended International Nonproprietary Names (Rec. INN): List 30

p. 8	nebivololum	*replace the chemical name by the following:*
	nebivolol	[2*R**[*R**[*R**(*S**)]]]-α,α'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2*H*-1-benzopyran-2-methanol]

MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES

Informations pharmaceutiques OMS, Vol. 1, No. 4, 1987

Dénominations communes internationales recommandées (DCI Rec.): Liste 27

p. 4 ebrotidinum
ébrotidine

remplacer le nom chimique par:
4-bromo-*N*-[(*E*)-[[2-[[[2-[(diaminométhylène)amino]thiazol-4-yl]méthyl]=sulfanyl]éthyl]amino]méthylène]benzènesulfonamide

Informations pharmaceutiques OMS, Vol. 3, No. 3, 1989

Dénominations communes internationales recommandées (DCI Rec.): Liste 29

p. 2 alteplasum
altéplase

remplacer la description et la formule brute par:
activateur du plasminogène (type tissulaire humain, partie protéique), forme glycosylée α
$C_{2569}H_{3894}N_{746}O_{781}S_{40}$

Informations pharmaceutiques OMS, Vol. 4, No. 3, 1990

Dénominations communes internationales recommandées (DCI Rec.): Liste 30

p. 9 nebivololum
nébivolol

remplacer le nom chimique par:
(1*RS*, 1'*RS*)-1,1'-[(2*RS*,2'*SR*)-bis(6-fluoro-3,4-dihydro-2*H*-chromén-2-yl)]-2,2'-iminodiéthanol

MODIFICACIONES A LAS LISTAS ANTERIORES

Información Farmacéutica, de la OMS, Vol. 1, No. 4, 1987

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 27

p. 4 ebrotidinum
ebrotidina

sustituyase el nombre químico por lo siguiente:
p-bromo-*N*-[(*E*)-[[2-[[[2-[(diaminometileno)amino]-4-tiazolil]metil]tio]etil]=amino]metileno]bencenosulfonamida

Información Farmacéutica, de la OMS, Vol. 3, No. 3, 1989

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 29

p. 2 alteplasum
alteplasa

sustituyanse la descripción y la fórmula molecular por las siguientes:
activador del plasminógeno (tipo tisular humano, fracción proteica), forma glicosilada α
$C_{2569}H_{3894}N_{746}O_{781}S_{40}$

Información Farmacéutica, de la OMS, Vol. 4, No. 3, 1990

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 30

p. 8 nebivololum
nebivolol

sustituyase el nombre químico por lo siguiente:
[2*R**[*R**[*R**(*S**)]]]-α,α'-[iminobis(metilen)]bis[6-fluoro-3,4-dihidro-2*H*-1-benzopiran-2-metanol]